195 related articles for article (PubMed ID: 20081809)
1. CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
Ong CW; Kim LG; Kong HH; Low LY; Iacopetta B; Soong R; Salto-Tellez M
Mod Pathol; 2010 Mar; 23(3):450-7. PubMed ID: 20081809
[TBL] [Abstract][Full Text] [Related]
2. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
3. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
4. CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling.
Hongo K; Tanaka J; Tsuno NH; Kawai K; Nishikawa T; Shuno Y; Sasaki K; Kaneko M; Hiyoshi M; Sunami E; Kitayama J; Takahashi K; Nagawa H
J Surg Res; 2012 Jun; 175(2):278-88. PubMed ID: 21601882
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
6. Expression of stem-cell markers OCT-4 and CD133: important prognostic factors in papillary renal cell carcinoma.
Kim K; Ro JY; Kim S; Cho YM
Hum Pathol; 2012 Dec; 43(12):2109-16. PubMed ID: 22944295
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
8. CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy.
Mia-Jan K; Jung SY; Kim IY; Oh SS; Choi E; Chang SJ; Kang TY; Cho MY
BMC Cancer; 2013 Mar; 13():166. PubMed ID: 23537343
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma.
Choi D; Lee HW; Hur KY; Kim JJ; Park GS; Jang SH; Song YS; Jang KS; Paik SS
World J Gastroenterol; 2009 May; 15(18):2258-64. PubMed ID: 19437567
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of expression of CD133 and Ki-67 in gastric cancer.
Saricanbaz I; Karahacioglu E; Ekinci O; Bora H; Kilic D; Akmansu M
Asian Pac J Cancer Prev; 2014; 15(19):8215-9. PubMed ID: 25339008
[TBL] [Abstract][Full Text] [Related]
11. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
[TBL] [Abstract][Full Text] [Related]
12. Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.
Ress AL; Stiegelbauer V; Schwarzenbacher D; Deutsch A; Perakis S; Ling H; Ivan C; Calin GA; Rinner B; Gerger A; Pichler M
Oncotarget; 2014 Sep; 5(18):8492-502. PubMed ID: 25261368
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
Xi HQ; Zhao P
J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
Huang Y; Yu H; Lei H; Xie C; Zhong Y
Med Oncol; 2014 Mar; 31(3):824. PubMed ID: 24469951
[TBL] [Abstract][Full Text] [Related]
16. Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
Lin LW; Lai PS; Chen YY; Chen CY
Pathol Int; 2021 Nov; 71(11):752-764. PubMed ID: 34528330
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.
Pitule P; Cedikova M; Daum O; Vojtisek J; Vycital O; Hosek P; Treska V; Hes O; Kralickova M; Liska V
Biomed Res Int; 2014; 2014():432139. PubMed ID: 24864242
[TBL] [Abstract][Full Text] [Related]
19. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients.
Takahashi S; Kamiyama T; Tomaru U; Ishizu A; Shida T; Osaka M; Sato Y; Saji Y; Ozaki M; Todo S
Oncol Rep; 2010 Nov; 24(5):1201-12. PubMed ID: 20878111
[TBL] [Abstract][Full Text] [Related]
20. Significance of CD133 expression in esophageal squamous cell carcinoma.
Okamoto H; Fujishima F; Nakamura Y; Zuguchi M; Ozawa Y; Takahashi Y; Miyata G; Kamei T; Nakano T; Taniyama Y; Teshima J; Watanabe M; Sato A; Ohuchi N; Sasano H
World J Surg Oncol; 2013 Mar; 11():51. PubMed ID: 23448401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
